US5925352A - Method of treating inflammation with antibodies to neutrophil chemotactic factor - Google Patents
Method of treating inflammation with antibodies to neutrophil chemotactic factor Download PDFInfo
- Publication number
- US5925352A US5925352A US08/935,560 US93556097A US5925352A US 5925352 A US5925352 A US 5925352A US 93556097 A US93556097 A US 93556097A US 5925352 A US5925352 A US 5925352A
- Authority
- US
- United States
- Prior art keywords
- ncf
- antibodies
- chemotactic factor
- neutrophil chemotactic
- neutrophil
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5421—IL-8
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/81—Packaged device or kit
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S930/00—Peptide or protein sequence
- Y10S930/01—Peptide or protein sequence
- Y10S930/12—Growth hormone, growth factor other than t-cell or b-cell growth factor, and growth hormone releasing factor; related peptides
Definitions
- the present invention relates to an isolated, synthetic preparation of a novel neutrophil-specific chemotactic factor (NCF), monoclonal antibodies having specific binding affinity for NCF and a clone containing the complete coding sequence for NCF.
- NCF neutrophil-specific chemotactic factor
- Activated monocytes/macrophages produce various mediators that cause inflammation. Among them are chemotactic factors which cause white blood cells to migrate into inflammatory sites where these factors area released. Neutrophils, the dominant leukocytes attracted by the chemotactic factors, are believed to play a critical role in the inflammatory reactions. Such diseases as rheumatoid arthritis, idiopathic pulmonary fibrosis and certain pathological inflammatory changes in many other conditions are believed to be caused by neutrophils and/or their products. However, a specific pro-inflammatory mediator released by tissue macrophages and other cells in response to imflammatory stmuli and leading to neutrophil-rich leukocyte accumulation in host defense and disease, has not heretofore been identified and isolated.
- NCF neutrophil-specific chemotactic factor
- It is another object of the present invention to provide a kit comprising a container containing the cDNA for NCF quantitation, detection or localization of NCF mRNA in a body sample.
- It is yet another object of the present invention to provide a kit comprising a container containing anti-NCF antibodies having specific binding affinity for NCF for quantitation, detection or localization of NCF in a body sample.
- FIG. 1 demonstrates translation of cDNA into NCF protein in reticulocyte lysate system
- FIGS. 2A-2D shows:
- NCF homogeneously pure, isolated, synthetic neutrophil chemotactic protein
- NCF of the present invention composed of the 72 amino acid residues as shown above, is achieved by commercially available polypeptide synthesizers.
- the NCF of the present invention is synthesized by standard techniques employing an expression vector containing in its genome the cloned complete coding sequence of NCF.
- Anti-NCF monoclonal antibodies of the present invention are prepared by standard hybridoma technology and utilized for purification and assaying purposes following standard immunological methodologies well known in the art.
- HPLC high performance liquid chromatography
- in situ hybridization assays Northern blotting analyses and the like are typical examples of the standard conventional techniques well known to one of ordinary skill in the art, which can be employed for isolation, localization, differentiation, detection, or measurement of the mRNA for NCF in biological samples.
- cDNA of the present invention due to its binding affinity for mRNA for NCF, for the first time makes it possible to analyze body samples such as joint fluid, sputum, alveolar lavage fluid, tissue samples and the like to detect the presence or absence of mRNA for NCF.
- the antibodies can also be utilized for diagnostic purposes to detect the NCF and to neutralize the NCF for alleviating any disease or anomalous conditions in which the presence of NCF is found to be a causative factor.
- a pharmaceutical composition for use in treating inflammatory condition comprises and anti-inflammatory effective amount of the anti-NCF monoclonal antibodies in pharmaceutically acceptable carrier, such as physiological saline, sterile non-toxic buffer and the like.
- a deposit of cDNA for NCF and of the hybridoma for anti-NCF monoclonal antibodies have been made at the ATCC, 10801 University Boulevard, Manassas, Va. 20110-2209 on Jan. 12, 1988 and Feb. 17, 1988, respectively, under the accession numbers 40412 and HB9647, respectively.
- the deposits shall be viably maintained, replacing if they became non-viable, for a period of 30 years from the date of the deposit, or for 5 years from the last date of request for a sample of the deposit, which is longer, and made available to the public without restriction in accordance with the provisions of the law.
- the Commissioner of Patents and Trademarks, upon request, shall have access to the deposits.
Abstract
An isloated, synthetic preparation of a novel neutrophil-specific chemotactic factor (NCF), monoclonal antibodies having specific binding affinity for NCF and a clone containing the complete cDNA coding sequence for NCF are disclosed.
Description
This is a divisonal of application Ser. No. 08/467,612 filed Jun. 6, 1995, now U.S. Pat. No. 5,698,196, which is a divisional of application Ser. No. 07/169,033, filed Mar. 16, 1988, now U.S. Pat. No. 5,652,338.
1. Technical Field
The present invention relates to an isolated, synthetic preparation of a novel neutrophil-specific chemotactic factor (NCF), monoclonal antibodies having specific binding affinity for NCF and a clone containing the complete coding sequence for NCF.
2. State of the Art
Activated monocytes/macrophages produce various mediators that cause inflammation. Among them are chemotactic factors which cause white blood cells to migrate into inflammatory sites where these factors area released. Neutrophils, the dominant leukocytes attracted by the chemotactic factors, are believed to play a critical role in the inflammatory reactions. Such diseases as rheumatoid arthritis, idiopathic pulmonary fibrosis and certain pathological inflammatory changes in many other conditions are believed to be caused by neutrophils and/or their products. However, a specific pro-inflammatory mediator released by tissue macrophages and other cells in response to imflammatory stmuli and leading to neutrophil-rich leukocyte accumulation in host defense and disease, has not heretofore been identified and isolated.
It is, therefore, an object of the present invention to provide a biologically active novel synthetic polypeptide acting as a neutrophil-specific chemotactic factor (NCF).
It is a further object of the present invention to provide a molecular clone containing the complete coding sequence for the synthesis of NCF by either prokaryotic or eukaryotic expression vectors.
It is a still further object of ,the present invention to provide monoclonal antibodies having specific binding affinity for NCF of the present invention.
It is another object of the present invention to provide a kit comprising a container containing the cDNA for NCF quantitation, detection or localization of NCF mRNA in a body sample.
It is yet another object of the present invention to provide a kit comprising a container containing anti-NCF antibodies having specific binding affinity for NCF for quantitation, detection or localization of NCF in a body sample.
Other objects and advantages will become evident from the following detailed description of the invention.
These and other objects, features and many of the attendant advantages of the invention will be better understood upon a reading of the following detailed description when considered in connection with the accompanying drawings wherein:
FIG. 1 demonstrates translation of cDNA into NCF protein in reticulocyte lysate system; and
FIGS. 2A-2D shows:
(a) Northern blot analysis of mRNA induction in lipopolysaccharide (LPS) stimulated peripheral blood monomuclear cells (PBMC);
(b) The time course of the accumulation of neutrophil chemotactic activity in culture media of PBMC after stimulation with LPS;
(c) Induction of NCF mRNA in PBMC by IL 1 or TNF, but not by IL 2, gamma-IFN, and alpha-IFN;
(d) HPLC gel filtration analysis of IL 1 and TNF induced neutrophil chemotactic activity.
The above and various other objects and advantages of the present invention are achieved by a homogeneously pure, isolated, synthetic neutrophil chemotactic protein, designated herein NCF, composed in the whole or in part only of the following amino acid sequence (single letter code):
NH2 -S-A-K-E-L-R-C-Q-C-I-K-T-Y-S-K-P-F-H-P-K-F-I-K-E-L-R-V -I-E-S-G-P-H-C-A-N-T-E-I-I-V-K-L-S-D-G-R-E-L-C-L-D-P-K-E-N-W-V-Q-R-V-V-E-K-F-L-K-R-A-E-N-S
Unless defined otherwise, all technica1 and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, the preferred methods and materials are now described. All publications mentioned hereunder are incorporated herein by reference. Unless mentioned otherwise, the techniques employed herein are standard methodologies well known to one of ordinary skill in the art.
Chemical synthesis of the NCF of the present invention composed of the 72 amino acid residues as shown above, is achieved by commercially available polypeptide synthesizers. Alternatively, the NCF of the present invention is synthesized by standard techniques employing an expression vector containing in its genome the cloned complete coding sequence of NCF. Anti-NCF monoclonal antibodies of the present invention are prepared by standard hybridoma technology and utilized for purification and assaying purposes following standard immunological methodologies well known in the art.
High performance liquid chromatography (HPLC), in situ hybridization assays, Northern blotting analyses and the like are typical examples of the standard conventional techniques well known to one of ordinary skill in the art, which can be employed for isolation, localization, differentiation, detection, or measurement of the mRNA for NCF in biological samples.
It should be noted that the fact that chemically synthesized polypeptide of the present invention at 10 nanomolar concentrations acts as a neutrophil attracting factor, is shown by the results presented in Table 1.
TABLE 1 ______________________________________ Chemotactic response of human neutrophils to chemically synthesized NCF. Concentration of Percentage of assay NCF, nanomolar neutrophils that migrated ______________________________________ 1000 23 100 34 10 32 1 5 0.1 1 Hanks medium 0.3 10-.sup.7 M fMet-Leu-Phe 40 ______________________________________ 1. It is typical for chemoattractant doseresponse curves to show an optimum, with a decreased response at concentrations above the optimum. 2. fMetLeu-Phe is a commonly used reference chemoattractant.
It may be pointed out that various stimuli cause the release or secretion of more than one chemoattractant. Without the cDNA of the present invention, it is clear, of course, that the presence, specificially of the mRNA for NCF as an involved factor in a particular clinico-pathological situation, could not be definitively identified and diagnosed. cDNA of the present invention due to its binding affinity for mRNA for NCF, for the first time makes it possible to analyze body samples such as joint fluid, sputum, alveolar lavage fluid, tissue samples and the like to detect the presence or absence of mRNA for NCF. Of course, the antibodies can also be utilized for diagnostic purposes to detect the NCF and to neutralize the NCF for alleviating any disease or anomalous conditions in which the presence of NCF is found to be a causative factor.
A pharmaceutical composition for use in treating inflammatory condition comprises and anti-inflammatory effective amount of the anti-NCF monoclonal antibodies in pharmaceutically acceptable carrier, such as physiological saline, sterile non-toxic buffer and the like.
A deposit of cDNA for NCF and of the hybridoma for anti-NCF monoclonal antibodies have been made at the ATCC, 10801 University Boulevard, Manassas, Va. 20110-2209 on Jan. 12, 1988 and Feb. 17, 1988, respectively, under the accession numbers 40412 and HB9647, respectively. The deposits shall be viably maintained, replacing if they became non-viable, for a period of 30 years from the date of the deposit, or for 5 years from the last date of request for a sample of the deposit, which is longer, and made available to the public without restriction in accordance with the provisions of the law. The Commissioner of Patents and Trademarks, upon request, shall have access to the deposits.
It is understood that the examples and embodiments described herein are for illustrative purposes only and that various modifications or changes in light thereof will be suggested to persons skilled in the art and are to be included within the spirit and purview of this application and scope of the appended claims.
Claims (2)
1. A method of treating an inflamrnatory condition, said method comprising administering to a host inflicted with an inflammnatory condition caused by or related to neutrophil chemotactic factor (NCF) polypeptide, an antiinflammatory effective amount of anti-NCF antibodies, wherein said antibodies have specific binding affinity for a neutrophil chemotactic factor polypeptide or part thereof where the polypeptide comprises the following amino acid sequence represented by single letter code;
NH2 -S-A-K-E-L-R-C-Q-C-I-K-T-Y-S-K-P-F-H-P-K-F-I-K-E-L-R- V-I-E-S-G-P-H-C-A-N-T-E-I-I-V-K-L-S-D-G-R-E-L-C-L-D-P-K-E-N-W-V-Q-R-V-V-E-K-F-L-K-R-A-E-N-S.
2. The method of claim 1, wherein said antibodies are monoclonal antibodies.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/935,560 US5925352A (en) | 1988-03-16 | 1997-09-23 | Method of treating inflammation with antibodies to neutrophil chemotactic factor |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US07/169,033 US5652338A (en) | 1988-03-16 | 1988-03-16 | Neutrophil chemotactic factor |
US08/467,612 US5698196A (en) | 1988-03-16 | 1995-06-06 | Antibodies specific for neutrophic chemotactic factor |
US08/935,560 US5925352A (en) | 1988-03-16 | 1997-09-23 | Method of treating inflammation with antibodies to neutrophil chemotactic factor |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US08/467,612 Division US5698196A (en) | 1988-03-16 | 1995-06-06 | Antibodies specific for neutrophic chemotactic factor |
Publications (1)
Publication Number | Publication Date |
---|---|
US5925352A true US5925352A (en) | 1999-07-20 |
Family
ID=22614006
Family Applications (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US07/169,033 Expired - Lifetime US5652338A (en) | 1988-03-16 | 1988-03-16 | Neutrophil chemotactic factor |
US08/467,612 Expired - Lifetime US5698196A (en) | 1988-03-16 | 1995-06-06 | Antibodies specific for neutrophic chemotactic factor |
US08/818,631 Expired - Lifetime US6376659B1 (en) | 1988-03-16 | 1997-03-14 | Nucleic acids encoding a novel neutrophil chemotactic factor |
US08/935,560 Expired - Lifetime US5925352A (en) | 1988-03-16 | 1997-09-23 | Method of treating inflammation with antibodies to neutrophil chemotactic factor |
US10/037,218 Expired - Lifetime US6475741B1 (en) | 1988-03-16 | 2001-11-09 | Neutrophil chemotactic factor cloned cDNA and monoclonal antibodies thereto |
Family Applications Before (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US07/169,033 Expired - Lifetime US5652338A (en) | 1988-03-16 | 1988-03-16 | Neutrophil chemotactic factor |
US08/467,612 Expired - Lifetime US5698196A (en) | 1988-03-16 | 1995-06-06 | Antibodies specific for neutrophic chemotactic factor |
US08/818,631 Expired - Lifetime US6376659B1 (en) | 1988-03-16 | 1997-03-14 | Nucleic acids encoding a novel neutrophil chemotactic factor |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/037,218 Expired - Lifetime US6475741B1 (en) | 1988-03-16 | 2001-11-09 | Neutrophil chemotactic factor cloned cDNA and monoclonal antibodies thereto |
Country Status (7)
Country | Link |
---|---|
US (5) | US5652338A (en) |
EP (1) | EP0414728A4 (en) |
JP (1) | JPH03504321A (en) |
AU (1) | AU626297B2 (en) |
CA (1) | CA1337642C (en) |
IL (1) | IL89600A (en) |
WO (1) | WO1989008665A1 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6475741B1 (en) | 1988-03-16 | 2002-11-05 | The United States Of America As Represented By The Department Of Health And Human Services | Neutrophil chemotactic factor cloned cDNA and monoclonal antibodies thereto |
US20040208873A1 (en) * | 2002-12-16 | 2004-10-21 | Medarex, Inc. | Human monoclonal antibodies against interleukin 8 (IL-8) |
US11572405B2 (en) | 2018-01-12 | 2023-02-07 | Bristol-Myers Squibb Company | Combination therapy with anti-IL-8 antibodies and anti-PD-1 antibodies for treating cancer |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3133305B2 (en) * | 1987-11-19 | 2001-02-05 | ノバルティス・アクチエンゲゼルシャフト | Neutrophil activator |
US5241049A (en) * | 1989-12-22 | 1993-08-31 | Zymogenetics, Inc. | Neutrophil chemoattractants |
US7041871B1 (en) * | 1995-10-10 | 2006-05-09 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US6300129B1 (en) | 1990-08-29 | 2001-10-09 | Genpharm International | Transgenic non-human animals for producing heterologous antibodies |
IE913192A1 (en) * | 1990-09-12 | 1992-02-25 | Scripps Research Inst | Active site of interleukin-8: polypeptide analogs and¹antibodies |
US6048972A (en) * | 1994-07-13 | 2000-04-11 | Chugai Pharmaceutical Co., Ltd. | Recombinant materials for producing humanized anti-IL-8 antibodies |
US5789539A (en) * | 1994-10-26 | 1998-08-04 | Repligen Corporation | Chemokine-like proteins and methods of use |
AU2576697A (en) * | 1996-04-19 | 1997-11-12 | Chugai Seiyaku Kabushiki Kaisha | Rheumatoid arthritis remedy containing anti-il-8 antibody as active ingredient |
US7122636B1 (en) | 1997-02-21 | 2006-10-17 | Genentech, Inc. | Antibody fragment-polymer conjugates and uses of same |
IL131406A0 (en) | 1997-02-21 | 2001-01-28 | Genentech Inc | Antibody fragment-polymer conjugates and humanized anti-il-8 monoclonal antibodies |
US6025158A (en) * | 1997-02-21 | 2000-02-15 | Genentech, Inc. | Nucleic acids encoding humanized anti-IL-8 monoclonal antibodies |
US6133426A (en) * | 1997-02-21 | 2000-10-17 | Genentech, Inc. | Humanized anti-IL-8 monoclonal antibodies |
US6458355B1 (en) | 1998-01-22 | 2002-10-01 | Genentech, Inc. | Methods of treating inflammatory disease with anti-IL-8 antibody fragment-polymer conjugates |
US7005504B2 (en) * | 1998-01-22 | 2006-02-28 | Genentech, Inc. | Antibody fragment-peg conjugates |
US6468532B1 (en) | 1998-01-22 | 2002-10-22 | Genentech, Inc. | Methods of treating inflammatory diseases with anti-IL-8 antibody fragment-polymer conjugates |
US7041870B2 (en) | 2000-11-30 | 2006-05-09 | Medarex, Inc. | Transgenic transchromosomal rodents for making human antibodies |
AU2002309063B8 (en) | 2001-05-11 | 2008-04-24 | Kyowa Kirin Co., Ltd. | Artificial human chromosome containing human antibody lambda light chain gene |
EP2003960B1 (en) | 2006-03-31 | 2015-06-10 | E. R. Squibb & Sons, L.L.C. | Transgenic animals expressing chimeric antibodies for use in preparing human antibodies |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4714674A (en) * | 1985-02-28 | 1987-12-22 | Genentech, Inc. | Chemotactic assay for immunogenicity |
US4797277A (en) * | 1987-09-22 | 1989-01-10 | Pharmacia Ab | Method for reperfusion therapy |
WO1989004325A1 (en) * | 1987-11-06 | 1989-05-18 | Ferring Arzneimittel Gmbh | Neutrophil-activating polypeptide, process for its manufacture and its use as a drug and diagnosticum |
WO1989004836A1 (en) * | 1987-11-19 | 1989-06-01 | Sandoz Ag | Neutrophil-activating factor |
WO1989010962A1 (en) * | 1988-05-02 | 1989-11-16 | Dainippon Pharmaceutical Co., Ltd | Process for producing a human neutrophil chemotactic factor polypeptide |
US4897348A (en) * | 1983-08-25 | 1990-01-30 | Sri International | Recombinant materials and methods for producing human connective tissue-activating peptide-III and analogs thereof |
US5401643A (en) * | 1988-08-29 | 1995-03-28 | Dainippon Pharmaceutical Co., Ltd. | Method of preparing an active human neutrophil chemotactic factor polypeptide |
US5451399A (en) * | 1989-11-29 | 1995-09-19 | Brigham And Women's Hospital | [ALA IL-8]77 and [SER IL-8]72 as Leukocyte adhesion inhibitors |
US5652338A (en) * | 1988-03-16 | 1997-07-29 | The United States Of America As Represented By The Department Of Health And Human Services | Neutrophil chemotactic factor |
-
1988
- 1988-03-16 US US07/169,033 patent/US5652338A/en not_active Expired - Lifetime
-
1989
- 1989-03-07 AU AU34284/89A patent/AU626297B2/en not_active Expired
- 1989-03-07 EP EP19890904929 patent/EP0414728A4/en not_active Withdrawn
- 1989-03-07 WO PCT/US1989/000976 patent/WO1989008665A1/en not_active Application Discontinuation
- 1989-03-07 JP JP1504682A patent/JPH03504321A/en active Pending
- 1989-03-14 IL IL8960089A patent/IL89600A/en unknown
- 1989-03-15 CA CA000593786A patent/CA1337642C/en not_active Expired - Lifetime
-
1995
- 1995-06-06 US US08/467,612 patent/US5698196A/en not_active Expired - Lifetime
-
1997
- 1997-03-14 US US08/818,631 patent/US6376659B1/en not_active Expired - Lifetime
- 1997-09-23 US US08/935,560 patent/US5925352A/en not_active Expired - Lifetime
-
2001
- 2001-11-09 US US10/037,218 patent/US6475741B1/en not_active Expired - Lifetime
Patent Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4897348A (en) * | 1983-08-25 | 1990-01-30 | Sri International | Recombinant materials and methods for producing human connective tissue-activating peptide-III and analogs thereof |
US4714674A (en) * | 1985-02-28 | 1987-12-22 | Genentech, Inc. | Chemotactic assay for immunogenicity |
US4797277A (en) * | 1987-09-22 | 1989-01-10 | Pharmacia Ab | Method for reperfusion therapy |
WO1989004325A1 (en) * | 1987-11-06 | 1989-05-18 | Ferring Arzneimittel Gmbh | Neutrophil-activating polypeptide, process for its manufacture and its use as a drug and diagnosticum |
WO1989004836A1 (en) * | 1987-11-19 | 1989-06-01 | Sandoz Ag | Neutrophil-activating factor |
US5652338A (en) * | 1988-03-16 | 1997-07-29 | The United States Of America As Represented By The Department Of Health And Human Services | Neutrophil chemotactic factor |
US5698196A (en) * | 1988-03-16 | 1997-12-16 | The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Antibodies specific for neutrophic chemotactic factor |
WO1989010962A1 (en) * | 1988-05-02 | 1989-11-16 | Dainippon Pharmaceutical Co., Ltd | Process for producing a human neutrophil chemotactic factor polypeptide |
US5306627A (en) * | 1988-05-02 | 1994-04-26 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Process for producing a human neutrophil chemotactic factor peptide and a recombinant expression vector for the said polypeptide |
US5401643A (en) * | 1988-08-29 | 1995-03-28 | Dainippon Pharmaceutical Co., Ltd. | Method of preparing an active human neutrophil chemotactic factor polypeptide |
US5451399A (en) * | 1989-11-29 | 1995-09-19 | Brigham And Women's Hospital | [ALA IL-8]77 and [SER IL-8]72 as Leukocyte adhesion inhibitors |
Non-Patent Citations (28)
Title |
---|
Gregory et al., Biochemical and Biophysical Research Communications 151(2), pp. 883 890 (1988). * |
Gregory et al., Biochemical and Biophysical Research Communications 151(2), pp. 883-890 (1988). |
Hickstein et al., Proc. Nat l Acad. Sci. USA, vol. 86, pp. 257 261 (1989). * |
Hickstein et al., Proc. Nat'l Acad. Sci. USA, vol. 86, pp. 257-261 (1989). |
Kownatzki, et al., Clin. Exp. Immunol., vol. 64(1), pp. 214 227 (1986). * |
Kownatzki, et al., Clin. Exp. Immunol., vol. 64(1), pp. 214-227 (1986). |
Matsushima et al, J. Exp. Med., vol. 167, pp. 1883 1893 (1988). * |
Matsushima et al, J. Exp. Med., vol. 167, pp. 1883-1893 (1988). |
Natanson et al. Annals of Internal Medicine, vol.:120 pp. 771 783, 1994. * |
Natanson et al. Annals of Internal Medicine, vol.:120 pp. 771-783, 1994. |
Schmid et al., The Journal of Immunology, vol. 139, No. 1, pp. 250 256 (1987). * |
Schmid et al., The Journal of Immunology, vol. 139, No. 1, pp. 250-256 (1987). |
Schroder et al., The Journal of Immunology, vol. 139, No. 10, pp. 3474 3483 (1987). * |
Schroder et al., The Journal of Immunology, vol. 139, No. 10, pp. 3474-3483 (1987). |
Shimizu et al., Scand. J. Immunol. vol. 28, pp. 675 685 (1988). * |
Shimizu et al., Scand. J. Immunol. vol. 28, pp. 675-685 (1988). |
Tanaka et al., Fed. of European Biochem. Societies, vol. 236, No. 2, pp. 467 470 (1988). * |
Tanaka et al., Fed. of European Biochem. Societies, vol. 236, No. 2, pp. 467-470 (1988). |
Von Damme et al., J. Exp. Med., vol. 167, pp. 1364 1376 (1988). * |
Von Damme et al., J. Exp. Med., vol. 167, pp. 1364-1376 (1988). |
Walz et al., Biochemical and Biophysical Research Communications, vol. 149, No. 2, pp. 755 761 (1987). * |
Walz et al., Biochemical and Biophysical Research Communications, vol. 149, No. 2, pp. 755-761 (1987). |
Yoshimura et al., Molecular Immunology, vol. 26, No. 1, pp. 87 93 (1989). * |
Yoshimura et al., Molecular Immunology, vol. 26, No. 1, pp. 87-93 (1989). |
Yoshimura et al., Proc. Nat l Acad. Sci. USA, vol. 84, pp. 9233 9237 (1987). * |
Yoshimura et al., Proc. Nat'l Acad. Sci. USA, vol. 84, pp. 9233-9237 (1987). |
Yoshimura et al., The Journal of Immunology, vol. 139, No. 3, pp. 788 793 (1987). * |
Yoshimura et al., The Journal of Immunology, vol. 139, No. 3, pp. 788-793 (1987). |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6475741B1 (en) | 1988-03-16 | 2002-11-05 | The United States Of America As Represented By The Department Of Health And Human Services | Neutrophil chemotactic factor cloned cDNA and monoclonal antibodies thereto |
US20040208873A1 (en) * | 2002-12-16 | 2004-10-21 | Medarex, Inc. | Human monoclonal antibodies against interleukin 8 (IL-8) |
US7282568B2 (en) | 2002-12-16 | 2007-10-16 | Medarex, Inc. | Human monoclonal antibodies against interleukin 8 (IL-8) |
US20080118517A1 (en) * | 2002-12-16 | 2008-05-22 | Medarex, Inc. | Human monoclonal antibodies against interleukin 8 (IL-8) |
US7622559B2 (en) | 2002-12-16 | 2009-11-24 | Genmab A/S | Human monoclonal antibodies against interleukin 8 (IL-8) |
US20100303823A1 (en) * | 2002-12-16 | 2010-12-02 | Genmab A/S | Human monoclonal antibodies against interleukin 8 (il-8) |
US8105588B2 (en) | 2002-12-16 | 2012-01-31 | Genmab A/S | Human monoclonal antibodies against interleukin 8 (IL-8) |
US8603469B2 (en) | 2002-12-16 | 2013-12-10 | Genmab A/S | Methods of treating cancer with human monoclonal antibodies against interleukin 8 |
US10066012B2 (en) | 2002-12-16 | 2018-09-04 | Cormorant Pharmaceuticals Ab | Human monoclonal antibodies against interleukin 8 (IL-8) |
US10253093B2 (en) | 2002-12-16 | 2019-04-09 | Cormorant Pharmaceuticals Ab | Human monoclonal antibodies against interleukin 8 (IL-8) |
US11339215B2 (en) | 2002-12-16 | 2022-05-24 | Cormorant Pharmaceuticals Ab | Methods of treating cancer with human monoclonal antibodies against interleukin 8 (IL-8) |
US11572405B2 (en) | 2018-01-12 | 2023-02-07 | Bristol-Myers Squibb Company | Combination therapy with anti-IL-8 antibodies and anti-PD-1 antibodies for treating cancer |
Also Published As
Publication number | Publication date |
---|---|
US5652338A (en) | 1997-07-29 |
EP0414728A4 (en) | 1992-04-15 |
US20020151706A1 (en) | 2002-10-17 |
JPH03504321A (en) | 1991-09-26 |
IL89600A (en) | 1994-12-29 |
AU3428489A (en) | 1989-10-05 |
US5698196A (en) | 1997-12-16 |
AU626297B2 (en) | 1992-07-30 |
EP0414728A1 (en) | 1991-03-06 |
US6475741B1 (en) | 2002-11-05 |
WO1989008665A1 (en) | 1989-09-21 |
CA1337642C (en) | 1995-11-28 |
IL89600A0 (en) | 1989-09-10 |
US6376659B1 (en) | 2002-04-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5925352A (en) | Method of treating inflammation with antibodies to neutrophil chemotactic factor | |
US4603106A (en) | Lipoprotein lipase suppression by endotoxin-induced mediator (shock assay) | |
Ross | Analysis of the different types of leukocyte membrane complement receptors and their interaction with the complement system | |
US7285275B2 (en) | Smooth muscle growth inhibitory composition, diagnostic method for arteriosclerosis, and kit therefor | |
EP0735818B1 (en) | MACROPHAGE INFLAMMATORY PROTEINS MIP-3, MIP-4 AND MIP-1gamma | |
EP0101681B1 (en) | Antibody to a mediator activity composition and its use in a pharmaceutical composition | |
JPH09118631A (en) | Tumor necrosis factor suppresive protein | |
JP2952750B2 (en) | Monoclonal antibody | |
KR970002917B1 (en) | Interleukin-1 inhibitors | |
US6309640B1 (en) | Lipoprotein lipase suppression by endotoxin-induced mediator (shock assay) | |
AU598861B2 (en) | Purification of recombinant interleukin-1 | |
US6419927B1 (en) | Method for reducing adverse effects of a human 70kDa mediator which results from endotoxin stimulation of macrophages | |
US5556767A (en) | Polynucleotide encoding macrophage inflammatory protein γ | |
CA2225675A1 (en) | Novel peptides derived from human heat shock protein 60 for treatment of diabetes, compositions, methods and kits | |
König et al. | Pore formation by the Escherichia coli alpha-hemolysin: role for mediator release from human inflammatory cells | |
US6001605A (en) | Gro genes | |
US5302384A (en) | Endothelial-derived II-8 adhesion inhibitor | |
Bergh et al. | Surprisingly high levels of anaphylatoxin C5a des Arg are extractable from psoriatic scales | |
JPH05505391A (en) | Endothelium-derived IL-8 | |
US5322838A (en) | Use of INHIB (the C3 β-chain) in the detection and inhibition of inflammation | |
Vasilescu et al. | Endotoxin-lnduced Release of Interleukin 6 and Interleukin 1β in Human Blood Is Independent of Tumor Necrosis Factor Alpha | |
Ensgraber et al. | Purification and characterization of a Salmonella typhimurium agglutinin from gut mucus secretions | |
US4665021A (en) | Diagnostic method of screening for immune deficiency in a nephrotic patient by determination of SIRS in the urine | |
US4771125A (en) | Human soluble immune response suppressor | |
IL107809A (en) | Method and kit for the detection of mRNA encoding a neutrophil polypeptide |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCF | Information on status: patent grant |
Free format text: PATENTED CASE |
|
CC | Certificate of correction | ||
FPAY | Fee payment |
Year of fee payment: 4 |
|
FPAY | Fee payment |
Year of fee payment: 8 |
|
FPAY | Fee payment |
Year of fee payment: 12 |